1
|
Mourtada F, Clement CH, Dauer LT, Baureus Koch C, Cosset JM, Doruff M, Damato A, Guedea F, Scalliet P, Thomadsen B, Pinillos-Ashton L, Small W. Occupational Radiological Protection in Brachytherapy. Ann ICRP 2021; 50:5-75. [PMID: 34503342 DOI: 10.1177/01466453211013514] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Affiliation(s)
- Firas Mourtada
- Chief of Clinical Physics, ChristianaCare, Newark, Delaware.,President, American Brachytherapy Society
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
2
|
Pérez-Montero H, Godino O, Lozano A, Asiáin L, Martínez I, Sánchez JJ, de BlasFernández R, Fernández E, Stefanovic M, García N, Martínez J, Guedea F, Navarro-Martin A. Long-term outcomes of spinal SBRT. Is it important to select the treatment time? Clin Transl Oncol 2021; 24:276-287. [PMID: 34342817 DOI: 10.1007/s12094-021-02684-9] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/10/2021] [Accepted: 07/08/2021] [Indexed: 10/20/2022]
Abstract
PURPOSE SBRT (stereotactic body radiation therapy) is widely used as a curative treatment in tumoral lesions and has become a fundamental tool for the treatment of spine metastasis. In this study, we present survival and toxicity outcomes of spine SBRT after a 2-year follow-up. METHODS/PATIENTS Data from spine SBRT treatments performed at our institution between March 2012 and February 2020 was collected. Medical records, including demographic, primary tumor, and treatment characteristics were reviewed. Patient follow-up included clinical evaluation, imaging, and blood tests. Toxicity was recorded according to CTCAE v4.0. RESULTS We analyzed 73 consecutive spine SBRT treatments in 60 patients. 39.7% of the cases had primary breast cancer and 23.3% had prostate cancer. Most cases (87.7%) were treated with a single SBRT fraction of 16 Gy. Median follow-up was 26.1 months (range 1.7-78.6), and 1- and 2-year overall survival (OS) rates were 96.9% and 84.2%, respectively. Local control (LC) rates at 1- and 2-years were 76.3% and 70.6%, respectively. Multivariate analysis identified histology as a prognostic factor for both OS and LC. Patients who underwent spine SBRT 6 months after the spinal lesion diagnosis had LC at 2 years of 88%, vs 61.7% for those who underwent SBRT before this period. No grade III or higher toxicity was reported. The vertebral compression fracture (VCF) rate was 4.1%. CONCLUSION Spine SBRT at our institution showed a 2-year LC of 70.6%, without G3 toxicities. Delaying SBRT at least 6 months to administer systemic treatment was related to an improvement in local control.
Collapse
Affiliation(s)
- H Pérez-Montero
- Radiation Oncology Department, Institut Català D'Oncologia, Barcelona, Spain
| | - O Godino
- Neurosurgery Department, Hospital Universitari de Bellvitge, Barcelona, Spain
| | - A Lozano
- Radiation Oncology Department, Institut Català D'Oncologia, Barcelona, Spain
| | - L Asiáin
- Radiation Oncology Department, Institut Català D'Oncologia, Barcelona, Spain
| | - I Martínez
- Radiation Oncology Department, Institut Català D'Oncologia, Barcelona, Spain
| | - J J Sánchez
- Radiodiagnostic Department, Hospital Universitari de Bellvitge, Barcelona, Spain
| | - R de BlasFernández
- Medical Physics and Radiation Protection Department, Institut Català D'Oncologia, Barcelona, Spain
| | - E Fernández
- Physical Medicine and Rehabilitation Department, Hospital Universitari de Bellvitge, Barcelona, Spain
| | - M Stefanovic
- Radiation Oncology Department, Institut Català D'Oncologia, Barcelona, Spain
| | - N García
- Radiation Oncology Department, Institut Català D'Oncologia, Barcelona, Spain
| | - J Martínez
- Radiation Oncology Department, Institut Català D'Oncologia, Barcelona, Spain
| | - F Guedea
- Radiation Oncology Department, Institut Català D'Oncologia, Barcelona, Spain
| | - A Navarro-Martin
- Radiation Oncology Department, Institut Català D'Oncologia, Barcelona, Spain.
| |
Collapse
|
3
|
Linares I, Berenguer Frances M, Cañas-Cortés R, Pujol-Canadell M, Nuñez M, Comas Antón S, Martinez E, Laplana M, Pérez-Montero H, Pla Farnós M, Both B, Guedea F. PO-1812: Peripheral immune cells and intraoperative radiation in low-risk breast cancer. Radiother Oncol 2020. [DOI: 10.1016/s0167-8140(21)01830-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
4
|
Lopes de Castro C, Fundowicz M, Roselló A, Jové J, Deantonio L, Aguiar A, Pisani C, Villà S, Boladeras A, Konstanty E, Kruszyna-Mochalska M, Milecki P, Jurado-Bruggeman D, Lencart J, Modolell I, Muñoz-Montplet C, Aliste L, Torras M, Puigdemont M, Carvalho L, Krengli M, Guedea F, Malicki J. PO-1174: Results of a multinational clinical audit for prostate cancer radiotherapy: the IROCA project. Radiother Oncol 2020. [DOI: 10.1016/s0167-8140(21)01192-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
5
|
Fundowicz M, Aguiar A, de Castro CL, Torras M, Deantonio L, Konstanty E, Mochalska MK, Macia M, Canals E, Caro M, Pisani C, Zwierzchowska D, Molero J, Eraso A, Lencart J, Muñoz-Montplet C, Carvalho L, Krengli M, Malicki J, Guedea F. PD-0431: Multicentre clinical radiotherapy audit in rectal cancer: results of the IROCA project. Radiother Oncol 2020. [DOI: 10.1016/s0167-8140(21)00453-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
6
|
Torras MG, Canals E, Muñoz-Montplet C, Vidal A, Jurado D, Eraso A, Villà S, Caro M, Molero J, Macià M, Puigdemont M, González-Muñoz E, López A, Guedea F, Borras JM. Improving quality of care and clinical outcomes for rectal cancer through clinical audits in a multicentre cancer care organisation. Radiat Oncol 2020; 15:28. [PMID: 32005123 PMCID: PMC6995177 DOI: 10.1186/s13014-020-1465-z] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/18/2019] [Accepted: 01/14/2020] [Indexed: 01/25/2023] Open
Abstract
Introduction Colorectal cancer treatment requires a complex, multidisciplinary approach. Because of the potential variability, monitoring through clinical audits is advisable. This study assesses the effects of a quality improvement action plan in patients with locally advanced rectal cancer and treated with radiotherapy. Methods Comparative, multicentre study in two cohorts of 120 patients each, selected randomly from patients diagnosed with rectal cancer who had initiated radiotherapy with a curative intent. Based on the results from a baseline clinical audit in 2013, a quality improvement action plan was designed and implemented; a second audit in 2017 evaluated its impact. Results Standardised information was present on 77.5% of the magnetic resonance imaging (MRI) staging reports. Treatment strategies were similar in all three study centres. Of the patients whose treatment was interrupted, just 9.7% received a compensation dose. There was an increase in MRI re-staging from 32.5 to 61.5%, and a significant decrease in unreported circumferential resection margins following neoadjuvant therapy (ypCRM), from 34.5 to 5.6% (p < 0.001). Conclusions The comparison between two clinical audits showed improvements in neoadjuvant radiotherapy in rectal cancer patients. Some indicators reveal areas in need of additional efforts, for example to reduce the overall treatment time.
Collapse
Affiliation(s)
- M G Torras
- Clinical Management Department, Institut Català d'Oncologia, Barcelona, Spain.
| | - E Canals
- Radiation Oncology Department, Institut Català d'Oncologia, Girona, Spain
| | - C Muñoz-Montplet
- Medical Physics and Radiation Protection Department, Institut Català d'Oncologia, Girona, Spain
| | - A Vidal
- Quality and Results Department, Institut Català d'Oncologia, Girona, Spain
| | - D Jurado
- Medical Physics and Radiation Protection Department, Institut Català d'Oncologia, Girona, Spain
| | - A Eraso
- Radiation Oncology Department, Institut Català d'Oncologia, Girona, Spain
| | - S Villà
- Radiation Oncology Department, Institut Català d'Oncologia, Badalona, Spain
| | - M Caro
- Radiation Oncology Department, Institut Català d'Oncologia, Badalona, Spain
| | - J Molero
- Medical Physics and Radiation Protection Department, Institut Català d'Oncologia, Girona, Spain
| | - M Macià
- Radiation Oncology Department, Institut Català d'Oncologia, Hospitalet del Llobregat, Barcelona, Spain
| | - M Puigdemont
- Hospital Tumor Registry, Institut Català d'Oncologia, Girona, Spain
| | - E González-Muñoz
- Quality and Results Department, Institut Català d'Oncologia, Girona, Spain
| | - A López
- Cancer Prevention and Control Program, Institut Català d'Oncologia, Hospitalet del Llobregat, Barcelona, Spain
| | - F Guedea
- Radiation Oncology Department, Institut Català d'Oncologia, Barcelona, Spain
| | - J M Borras
- Department of Clinical Sciences, IDIBELL, University of Barcelona, Barcelona, Spain
| |
Collapse
|
7
|
Almendros S, Berenguer-Francés MA, Ferrer-González F, Boladeras A, Guix I, Guedea F. Predictive factors for abiraterone withdrawal syndrome. Actas Urol Esp 2019; 43:300-304. [PMID: 31060755 DOI: 10.1016/j.acuro.2019.01.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/23/2018] [Revised: 12/03/2018] [Accepted: 01/20/2019] [Indexed: 12/24/2022]
Abstract
INTRODUCTION AND OBJECTIVE Abiraterone withdrawal syndrome (AWS) is characterized by a transient decrease in the PSA after abiraterone acetate (AA) treatment discontinuation in patients diagnosed with metastatic castration-resistant prostate cancer (mCRPC). The aim of our study is to identify the possible predictive factors of AWS at diagnosis. MATERIALS AND METHODS We performed a retrospective study of 70 patients treated with AA at the Institut Català d'Oncologia - L'Hospitalet between 2015 and 2017. RESULTS 11 patients presented AWS. The mean age at diagnosis was 65.73 years and the mean age of presentation was 74.18 years. Patients were in the ninth treatment cycle. The median PSA was: 30.5ng/ml at diagnosis, 33.24ng/ml in the AWS, and 15.78ng/ml before starting another treatment. The median follow-up period after AWS was 8.2 months. The predictive factors of AWS would be: high PSA (p=.002), ISUP≥4 (p=.002) and stage IV at diagnosis (p<.001). Patients with a T stage present high risk, but without statistical significance. An AUC of 0.84 was obtained, with a 95% CI between 0.77 and 0.92 (p<.001). CONCLUSIONS The incidence of AWS is not negligible, describing prolonged responses after AA withdrawal, including the possibility of increased overall survival. These results could entail new treatment schemes for mCRPC.
Collapse
Affiliation(s)
- S Almendros
- Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, España; Servicio de Oncología Radioterápica, Institut Català d'Oncologia - L'Hospitalet, L'Hospitalet de Llobregat, Barcelona, España
| | - M A Berenguer-Francés
- Servicio de Oncología Radioterápica, Institut Català d'Oncologia - L'Hospitalet, L'Hospitalet de Llobregat, Barcelona, España.
| | - F Ferrer-González
- Servicio de Oncología Radioterápica, Institut Català d'Oncologia - L'Hospitalet, L'Hospitalet de Llobregat, Barcelona, España
| | - A Boladeras
- Servicio de Oncología Radioterápica, Institut Català d'Oncologia - L'Hospitalet, L'Hospitalet de Llobregat, Barcelona, España
| | - I Guix
- Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, España; Servicio de Oncología Radioterápica, Institut Català d'Oncologia - L'Hospitalet, L'Hospitalet de Llobregat, Barcelona, España
| | - F Guedea
- Servicio de Oncología Radioterápica, Institut Català d'Oncologia - L'Hospitalet, L'Hospitalet de Llobregat, Barcelona, España
| |
Collapse
|
8
|
Linares I, Berenguer M, Martínez E, Laplana M, Cañas R, Comas S, Pérez-Montero H, Ventura M, Guedea F. PO-1072 INTRABEAM: precision hypo-fractionated radiotherapy with a systemic immune response. Radiother Oncol 2019. [DOI: 10.1016/s0167-8140(19)31492-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
9
|
Navarro-Martin A, Linares I, Berenguer M, Cañas R, Guedea F. EP-2164 Pilot Study: Systemic response after lung SBRT analyzing immune Cells phenotyping. Radiother Oncol 2019. [DOI: 10.1016/s0167-8140(19)32584-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
10
|
Walker V, Jacob S, Crijns A, Langendijk J, Spoor D, Vliegenthart R, Combs S, Mayinger M, Borm K, Eraso A, Guedea F, Fiuza M, Constantino Rosa Santos S, Tamarat R, Laurier D, Ferrières J, Cardis E, Mousseaux E. Radiotherapy-induced cardiotoxicity in breast cancer patients: New approaches of early detection and prediction based on cardiac imaging and circulating biomarkers (European MEDIRAD EARLY-HEART study). Archives of Cardiovascular Diseases Supplements 2019. [DOI: 10.1016/j.acvdsp.2018.10.275] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
11
|
Torras MG, Canals E, Jurado-Bruggeman D, Marín-Borras S, Macià M, Jové J, Boladeras AM, Muñoz-Montplet C, Molero J, Picón C, Puigdemont M, Aliste L, Torrents A, Guedea F, Borras JM. Clinical Audit of the Radiotherapy Process in Rectal Cancer: Clinical Practice Guidelines and Quality Certification Do Not Avert Variability in Clinical Practice. Transl Oncol 2018; 11:794-799. [PMID: 29704788 PMCID: PMC6058082 DOI: 10.1016/j.tranon.2018.03.015] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2018] [Accepted: 03/29/2018] [Indexed: 12/18/2022] Open
Affiliation(s)
- M G Torras
- Clinical Management Department, Institut Català d'Oncologia, Spain.
| | - E Canals
- Radiation Oncology Department, Institut Català d'Oncologia, Girona, Spain
| | - D Jurado-Bruggeman
- Medical Physics and Radiation Protection Department, Institut Català d'Oncologia, Girona, Spain
| | - S Marín-Borras
- Radiation Oncology Department, Institut Català d'Oncologia, L'Hospitalet de Llobregat, Spain
| | - M Macià
- Radiation Oncology Department, Institut Català d'Oncologia, L'Hospitalet de Llobregat, Spain
| | - J Jové
- Radiation Oncology Department, Institut Català d'Oncologia, Badalona, Spain
| | - A M Boladeras
- Radiation Oncology Department, Institut Català d'Oncologia, L'Hospitalet de Llobregat, Spain
| | - C Muñoz-Montplet
- Medical Physics and Radiation Protection Department, Institut Català d'Oncologia, Spain
| | - J Molero
- Medical Physics and Radiation Protection Department, Institut Català d'Oncologia, Badalona, Spain
| | - C Picón
- Medical Physics and Radiation Protection Department, Institut Català d'Oncologia, L'Hospitalet de Llobregat, Spain
| | - M Puigdemont
- Hospital Tumor Registry, Institut Català d'Oncologia, Girona, Spain
| | - L Aliste
- Catalonian Cancer Strategy, Department of Health, Barcelona
| | - A Torrents
- Catalonian Cancer Strategy, Department of Health, Barcelona
| | - F Guedea
- Radiation Oncology Department, Institut Català d'Oncologia, Spain
| | - J M Borras
- Catalonian Cancer Strategy, Department of Health, Barcelona; Radiation Oncology Department, Institut Català d'Oncologia, Spain; Clinical Sciences Department, IDIBELL, University of Barcelona
| |
Collapse
|
12
|
Schäfer R, Strnad V, Polgár C, Uter W, Hildebrandt G, Ott O, Kauer-Dorner D, Knauerhase H, Major T, Lyczek J, Guinot J, Dunst J, Gutierrez Miguelez C, Slampa P, Allgäuer M, Lössl K, Kovacs G, Fietkau R, Resch A, Kulik A, Arribas L, Niehoff P, Guedea F, Gall C, Polat B. OC-0326: QOL After APBI (Multicatheter Brachytherapy) Versus WBI: 5-Year Results, Phase 3 GEC-ESTRO Trial. Radiother Oncol 2018. [DOI: 10.1016/s0167-8140(18)30636-4] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
13
|
Ferrer F, Pont A, De Blas R, Boladeras A, Garin O, Ventura M, Garcia E, Gutierrez C, Zardoya E, Rojas F, Bavestrello P, Laplana M, Mases J, Castells M, Guix I, Suarez J, Picon C, Pera J, Ferrer M, Guedea F. Toxicity and Quality of Life (QoL) Comparison between Two Escalation Dose Fractionation Protocols With Steroatactic Body Radiation Therapy in Prostate Cancer. Int J Radiat Oncol Biol Phys 2017. [DOI: 10.1016/j.ijrobp.2017.06.1155] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
14
|
Boladeras A, Ferrer F, Navarro V, De Blas R, Cunillera O, Mateo D, Gutierrez C, Villa S, Martinez E, Pera J, Ferrer M, Guedea F. Association Between Dose-Volume Histograms and Health-Related Quality of Life in Patients with Prostate Cancer Treated with External Beam Radiation Therapy. Int J Radiat Oncol Biol Phys 2016. [DOI: 10.1016/j.ijrobp.2016.06.1340] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
15
|
Ferrer F, Ballon K, Boladeras A, De Blas R, Najjari D, Ventura M, Bavestrello P, Rojas F, Bejar S, Zardoya E, Martinez E, Comas S, Gutierrez C, Pera J, Picon C, Guedea F. Pelvic Volumetric Modulated Arc Therapy (VMAT) for Prostate for Locally Advanced Prostate Cancer. Int J Radiat Oncol Biol Phys 2016. [DOI: 10.1016/j.ijrobp.2016.06.1249] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
16
|
Ferrer F, Pont A, Letelier H, Garin O, De Blas R, Boladeras A, Garcia E, Zardoya E, Najjari D, Gonzalo P, Castells M, Mariño A, Gutierrez C, Ventura M, Rojas F, Bavestrello P, Suarez J, Picon C, Guedea F. Early Experience and Quality of Life Comparison in Prostate Cancer Brachytherapy Versus Phase I-II Stereotactic Body Radiation Therapy Trials. Int J Radiat Oncol Biol Phys 2016. [DOI: 10.1016/j.ijrobp.2016.06.1285] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
17
|
Polgár C, Strnad V, Ott O, Hildebrandt G, Kauer-Dorner D, Knauerhase H, Major T, Lyczek J, Guinot J, Dunst J, Gutierrez Miguelez C, Slampa P, Allgäuer M, Lössl K, Polat B, Kovács G, Fischedick A, Wendt T, Hindemith M, Resch A, Niehoff P, Guedea F, Pötter R, Gall C, Uter W. OC-0481: Late toxicity and cosmesis after APBI with brachytherapy vs WBI: 5-year results of a phase III trial. Radiother Oncol 2016. [DOI: 10.1016/s0167-8140(16)31730-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
18
|
Henríquez-Hernández LA, Valenciano A, Foro-Arnalot P, Álvarez-Cubero MJ, Cozar JM, Suárez-Novo JF, Castells-Esteve M, Fernández-Gonzalo P, De-Paula-Carranza B, Ferrer M, Guedea F, Sancho-Pardo G, Craven-Bartle J, Ortiz-Gordillo MJ, Cabrera-Roldán P, Rodríguez-Melcón JI, Herrera-Ramos E, Rodríguez-Gallego C, Lara PC. Association between single-nucleotide polymorphisms in DNA double-strand break repair genes and prostate cancer aggressiveness in the Spanish population. Prostate Cancer Prostatic Dis 2016; 19:28-34. [PMID: 26754263 DOI: 10.1038/pcan.2015.63] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/22/2015] [Revised: 10/27/2015] [Accepted: 11/24/2015] [Indexed: 02/07/2023]
Abstract
BACKGROUND Novel predictors of prognosis and treatment response for prostate cancer (PCa) are required to better individualize treatment. Single-nucleotide polymorphisms (SNPs) in four genes directly (XRCC5 (X-ray repair complementing defective repair in Chinese hamster cells 5) and XRCC6 (X-ray repair complementing defective repair in Chinese hamster cells 6)) or indirectly (PARP1 and major vault protein (MVP)) involved in non-homologous end joining were examined in 494 Spanish PCa patients. METHODS A total of 22 SNPs were genotyped in a Biotrove OpenArray NT Cycler. Clinical tumor stage, diagnostic PSA serum levels and Gleason score at diagnosis were obtained for all participants. Genotypic and allelic frequencies were determined using the web-based environment SNPator. RESULTS (XRCC6) rs2267437 appeared as a risk factor for developing more aggressive PCa tumors. Those patients carrying the GG genotype were at higher risk of developing bigger tumors (odds ratio (OR)=2.04, 95% confidence interval (CI) 1.26-3.29, P=0.004), present higher diagnostic PSA levels (OR=2.12, 95% CI 1.19-3.78, P=0.011), higher Gleason score (OR=1.65, 95% CI 1.01-2.68, P=0.044) and D'Amico higher risk tumors (OR=2.38, 95% CI 1.24-4.58, P=0.009) than those patients carrying the CC/CG genotypes. Those patients carrying the (MVP) rs3815824 TT genotype were at higher risk of presenting higher diagnostic PSA levels (OR=4.74, 95% CI 1.40-16.07, P=0.013) than those patients carrying the CC genotype. When both SNPs were analyzed in combination, those patients carrying the risk genotypes were at higher risk of developing D'Amico higher risk tumors (OR=3.33, 95% CI 1.56-7.17, P=0.002). CONCLUSIONS We believe that for the first time, genetic variants at XRCC6 and MVP genes are associated with risk of more aggressive disease, and would be taken into account when assessing the malignancy of PCa.
Collapse
Affiliation(s)
- L A Henríquez-Hernández
- Radiation Oncology Department, Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas, Spain.,Instituto Canario de Investigación del Cáncer, Las Palmas, Spain.,Clinical Sciences Department, Universidad de Las Palmas de Gran Canaria, Las Palmas, Spain
| | - A Valenciano
- Instituto Canario de Investigación del Cáncer, Las Palmas, Spain
| | - P Foro-Arnalot
- Radiation Oncology Department, Institud d'Oncologia Radioteràpica, Hospital de la Esperanza, Parc de Salut Mar, Barcelona, Spain
| | - M J Álvarez-Cubero
- Laboratory of Genetic Identification, Legal Medicine and Toxicology Department, Facultad de Medicina, Universidad de Granada, Granada, Spain.,GENYO, Pfizer-University of Granada-Andalusian Government Centre for Genomics and Oncological Research, Granada, Spain
| | - J M Cozar
- Department of Urology, Hospital Universitario Virgen de las Nieves, Granada, Spain
| | - J F Suárez-Novo
- Department of Urology, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain
| | - M Castells-Esteve
- Department of Urology, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain
| | | | | | - M Ferrer
- Health Services Research Group, Institut de Recerca Hospital del Mar (IMIM), Barcelona, Spain
| | - F Guedea
- Department of Radiation Oncology, Institut Català d'Oncologia (ICO), L'Hospitalet de Llobregat, Barcelona, Spain
| | - G Sancho-Pardo
- Radiation Oncology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
| | - J Craven-Bartle
- Radiation Oncology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
| | - M J Ortiz-Gordillo
- Radiation Oncology Department, Hospital Universitario Virgen del Rocío, Sevilla, Spain
| | - P Cabrera-Roldán
- Radiation Oncology Department, Hospital Universitario Virgen del Rocío, Sevilla, Spain
| | - J I Rodríguez-Melcón
- Radiation Oncology Department, Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas, Spain.,Instituto Canario de Investigación del Cáncer, Las Palmas, Spain
| | - E Herrera-Ramos
- Department of Immunology, Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas, Spain.,Department of Medical and Surgical Sciences, Universidad de Las Palmas de Gran Canaria, Las Palmas, Spain
| | - C Rodríguez-Gallego
- Department of Immunology, Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas, Spain
| | - P C Lara
- Radiation Oncology Department, Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas, Spain.,Instituto Canario de Investigación del Cáncer, Las Palmas, Spain.,Clinical Sciences Department, Universidad de Las Palmas de Gran Canaria, Las Palmas, Spain
| |
Collapse
|
19
|
Ferrer F, Mendez G, Chiruzzi C, Letelier H, Boladeras A, De Blas R, Piñeiro R, Galdeano M, Najjari D, Zardoya E, Chavez R, Ventura M, Martinez E, Gutierrez C, Picon C, Pera J, Guedea F. Overall Treatment Time and Charlson Score Impact on Toxicity of Intensity Modulated Arc Therapy With Simultaneous Integrated Boost to Prostate for Intermediate- or High-Risk Prostate Cancer. Int J Radiat Oncol Biol Phys 2015. [DOI: 10.1016/j.ijrobp.2015.07.1084] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
20
|
Letelier H, Gutiérrez C, Martínez E, Galdeano M, Marín S, Pera J, Moreno S, Pino F, González F, García M, Guedea F. EP-1266: Interstitial brachytherapy using MUPIT in locally advanced or recurrent gynecological malignancies. Radiother Oncol 2015. [DOI: 10.1016/s0167-8140(15)41258-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
21
|
Ferrer Gonzalez F, Letelier H, De Blas R, Boladeras A, Piñeiro R, Galdeano M, Najjari D, Castells M, Garcia E, Zardoya E, Suarez J, Martinez E, Gutierrez C, Pera J, Picon C, Guedea F. EP-1258: Early experience in SBRT with VMAT and flattening filterfree (FFF) beams. Phase I-II trial. Radiother Oncol 2015. [DOI: 10.1016/s0167-8140(15)41250-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
22
|
Letelier H, Lozano A, Navarro A, Mesía R, Mesía R, Vásquez S, Navarro V, Mañós M, De Blas R, Guedea F. EP-1153 Nasopharyngeal carcinoma treated with intensitymodulated radiotherapy in a non-endemic area. Radiother Oncol 2015. [DOI: 10.1016/s0167-8140(15)41145-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
23
|
Ferrer F, Mendez M, Letelier H, Boladeras A, Piñeiro R, Chiruzzi C, Galdeano M, Najjari D, Sancho I, Chavez R, Picon C, Pera J, Guedea F. EP-1229: Overall treatment time and toxicity of IMAT with integrated boost for intermediate or high-risk prostate cancer. Radiother Oncol 2015. [DOI: 10.1016/s0167-8140(15)41221-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
24
|
Lopez Guerra JL, Rivin E, Guedea F, Ortiz MJ. Radiation oncology in Latin speaking countries: A link between Europe and Latin America. Rep Pract Oncol Radiother 2014; 19:227-9. [PMID: 25061515 DOI: 10.1016/j.rpor.2013.06.004] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022] Open
Affiliation(s)
- J L Lopez Guerra
- Virgen del Rocío University Hospital, Department of Radiation Oncology, Seville, Spain
| | - E Rivin
- Department of Radiation Oncology, Institut de cancérologie Gustave Roussy, Villejuif, Paris, France
| | - F Guedea
- Department of Radiation Oncology, Institut Català d'Oncologia, L'Hospitalet de Llobregat, Barcelona, Spain
| | - M J Ortiz
- Virgen del Rocío University Hospital, Department of Radiation Oncology, Seville, Spain
| |
Collapse
|
25
|
Carvajal C, Navarro A, De Blas R, Cacicedo J, Bilbao P, Guedea F. EP-1390: Lung stereotactic body radiotherapy for oligometastases of colorectal tumors: First outcomes. Radiother Oncol 2014. [DOI: 10.1016/s0167-8140(15)31508-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
26
|
Ferrer F, Guedea F, Pardo Y, Ferrer M, Suarez J, Hervás A, Mariño A, Herruzo I, Ortiz M, Sancho G. Quality of Life Impact of Treatments for Localized Prostate Cancer. Int J Radiat Oncol Biol Phys 2013. [DOI: 10.1016/j.ijrobp.2013.06.982] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
27
|
Riou O, Castan F, Picaud F, Gutiérrez C, Llacer Moscardo C, Dubois J, Cambray M, Lemanski C, Guedea F, Azria D, Ferrer F, Delannes M. Curiethérapie du cancer du canal anal : une étude multicentrique du Groupe d’oncologie Catalan Occitan. Cancer Radiother 2013. [DOI: 10.1016/j.canrad.2013.07.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
28
|
Navarro Martin A, Piñeiro Retif R, Arnaiz M, Ramos R, Aso S, Garcia E, Martinez J, Sancho I, Guedea F. Single fraction of SBRT in pulmonary lesions. Rep Pract Oncol Radiother 2013. [DOI: 10.1016/j.rpor.2013.03.319] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022] Open
|
29
|
Guedea F, Fernández P, Mariño A, Sancho G, Herruzo I, Hervás A, Ortiz M, Macías V, Suárez J, Ferrer M. PD-0119 QUALITY OF LIFE (QOL) FOR PROSTATE CANCER AFTER PROSTECTOMY VS BRACHYTHERAPY VS EBRT WITH A FOLLOW-UP OF 5 YEARS. Radiother Oncol 2012. [DOI: 10.1016/s0167-8140(12)70458-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
30
|
Guedea F, Macià M, Sanchez Calzado JA, Ramos A, Lopez Torrecilla JL, Herruzo I, Contreras J, Romero J, Willisch P. Treatment of cancer with drugs: a controversy. Ann Oncol 2011; 22:747-748. [PMID: 21343385 DOI: 10.1093/annonc/mdq760] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- F Guedea
- Department of Radiation Oncology, Catalan Institute of Oncology, Barcelona.
| | - M Macià
- Department of Radiation Oncology, Catalan Institute of Oncology, Barcelona
| | | | - A Ramos
- Department of Radiation Oncology, Hospital Universitario Ramón y Cajal, Madrid
| | | | - I Herruzo
- Department of Radiation Oncology, Hospital General Universitario 'Carlos Haya', Malaga
| | - J Contreras
- Department of Radiation Oncology, Hospital General Universitario 'Carlos Haya', Malaga
| | - J Romero
- Deppartment of Radiation Oncology, Clínica Universitaria Puerta de Hierro, Madrid
| | - P Willisch
- Deartment of Radiation Oncology, Hospital Meixoeiro, Vigo, Spain
| | | |
Collapse
|
31
|
Miguélez CG, Pera J, Mitjana JC, Martinez E, Piulats J, Guedea F. 824 poster CONSERVATIVE TREATMENT WITH BRACHYTHERAPY FOR UVEAL MELANOMA: MORE THAN 300 CASES FROM THE INSTITUT CATALÀ D'ONCOLOGIA. Radiother Oncol 2011. [DOI: 10.1016/s0167-8140(11)70946-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
32
|
Lopez Guerra J, Lozano A, Pera J, Gutiérrez C, Cambray M, Ferrer F, Ortiz M, Guedea F. Twenty-year Experience in the Management of Anal Carcinoma with Interstitial Brachytherapy. Int J Radiat Oncol Biol Phys 2010. [DOI: 10.1016/j.ijrobp.2010.07.779] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
33
|
Maldonado X, Sancho G, Ferrer M, Guedea F. Revisión crítica del uso de radioterapia como tratamiento inicial del cáncer de próstata localizado. Actas Urol Esp 2010. [DOI: 10.1016/j.acuro.2010.04.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
34
|
Maldonado X, Sancho G, Ferrer M, Guedea F. Revisión crítica del uso de radioterapia como tratamiento inicial del cáncer de próstata localizado. Actas Urol Esp 2010. [DOI: 10.4321/s0210-48062010000500001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
35
|
Maldonado X, Sancho G, Ferrer M, Guedea F. [Critical review of the use of radiotherapy as initial treatment of localized prostate cancer]. Actas Urol Esp 2010; 34:401-402. [PMID: 20470711] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/29/2023]
|
36
|
Guedea F, Ferrer M, Pera J, Aguiló F, Boladeras A, Suárez JF, Cunillera O, Ferrer F, Pardo Y, Martínez E, Ventura M. Quality of life two years after radical prostatectomy, prostate brachytherapy or external beam radiotherapy for clinically localised prostate cancer: the Catalan Institute of Oncology/Bellvitge Hospital experience. Clin Transl Oncol 2009; 11:470-8. [PMID: 19574206 DOI: 10.1007/s12094-009-0387-x] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
OBJECTIVE The objective was to compare the short- and long-term impact of 3 different treatment modalities on health-related quality of life (HRQOL) in patients treated for localised prostate cancer at a single centre in Catalonia, Spain. MATERIAL AND METHODS This was a longitudinal, prospective study of 304 patients from a single centre in Catalonia, Spain. Patients underwent 1 of 3 treatment procedures: radical prostatectomy (114 patients), external beam radiation (134) or interstitial brachytherapy (56). HRQOL was assessed by both general and specific questionnaires, including the SF-36 health survey and the Expanded Prostate Cancer Index Composite (EPIC). Interviews were administered prior to treatment and at months 1, 3, 6, 12 and 24. One-way analysis of variance and generalised estimating equations models were constructed to assess between group differences in HRQOL. RESULTS After initial deterioration, HRQOL scores partially recovered, although significant differences between treatment groups persisted at two years. Worsening of urinary incontinence was especially marked for the radical prostatectomy group (11.45, p=0.005), while deterioration in the urinary irritative/obstructive domain was worse following brachytherapy treatment (4.76, p=0.025). Decline in sexual function was significantly greater for the radical prostatectomy group than for the brachytherapy group (18.74, p<0.001). No significant between-group differences were observed in bowel domain scores. CONCLUSIONS Quality of life 2 years after treatment for prostate cancer shows wide variability. Radical prostatectomy had the largest negative impact on the sexual and urinary incontinence domains. Differences between external radiation and brachytherapy were relatively small. Brachytherapy led to a moderate increase in urinary irritation compared to the other 2 groups.
Collapse
Affiliation(s)
- F Guedea
- Catalan Institute of Oncology, L'Hospitalet de Llobregat, Barcelona, Spain
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
37
|
Guedea F, Venselaar J, Ventura M, Londres B, Van Limbergen E, Mazeron J, National coordinators P. 149 poster: Patterns of Care for Brachytherapy (PCB): Preliminary Results. Radiother Oncol 2009. [DOI: 10.1016/s0167-8140(15)34406-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
38
|
Peiffert D, Mazeron JJ, Guedea F, Nisin R. La curiethérapie en France en 2002: résultats de l'enquête PCBE de l'ESTRO. Cancer Radiother 2007; 11:146-9. [PMID: 17291805 DOI: 10.1016/j.canrad.2006.12.003] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/25/2006] [Revised: 12/13/2006] [Accepted: 12/19/2006] [Indexed: 10/23/2022]
Abstract
The authors report the results of the Patterns of Care for Brachytherapy in Europe (PCBE) throughout France. Responses were obtained for 91% of the Radiation Oncology departments, which have declared using brachytherapy for 67, and gave detailed data for 49 ones. The equipments and treated tumours were recorded. LDR brachytherapy remained the most often used (53.5%), followed by HDR (28%). PDR represented 5.5% and permanent implants 11%. The authors discuss the development of new equipment, with an aggregation of the structures, and an increase of the PDR and prostate implants use.
Collapse
Affiliation(s)
- D Peiffert
- Département de radiothérapie, centre Alexis-Vautrin, 54511 Vandoeuvre-lès-Nancy cedex, France.
| | | | | | | |
Collapse
|
39
|
Cataliotti L, De Wolf C, Holland R, Marotti L, Perry N, Redmond K, Rosselli Del Turco M, Rijken H, Kearney N, Ellis IO, Di Leo A, Orecchia R, Noel A, Andersson M, Audretsch W, Bjurstam N, Blamey RW, Blichert-Toft M, Bosmans H, Burch A, Bussolati G, Christiaens MR, Colleoni M, Cserni G, Cufer T, Cush S, Damilakis J, Drijkoningen M, Ellis P, Foubert J, Gambaccini M, Gentile E, Guedea F, Hendriks J, Jakesz R, Jassem J, Jereczek-Fossa BA, Laird O, Lartigau E, Mattheiem W, O'higgins N, Pennery E, Rainsbury D, Rutgers E, Smola M, Van Limbergen E, von Smitten K, Wells C, Wilson R. Guidelines on the standards for the training of specialised health professionals dealing with breast cancer. Eur J Cancer 2007; 43:660-75. [PMID: 17276672 DOI: 10.1016/j.ejca.2006.12.008] [Citation(s) in RCA: 67] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/19/2006] [Revised: 11/29/2006] [Accepted: 12/04/2006] [Indexed: 01/30/2023]
Abstract
According to EUSOMA position paper 'The requirements of a specialist breast unit', each breast unit should have a core team made up of health professionals who have undergone specialist training in breast cancer. In this paper, on behalf of EUSOMA, authors have identified the standards of training in breast cancer, to harmonise and foster breast care training in Europe. The aim of this paper is to contribute to the increase in the level of care in a breast unit, as the input of qualified health professionals increases the quality of breast cancer patient care.
Collapse
|
40
|
Guedea F, Ellison T, Heeren G, Ventura M, François G, Mazeron JJ, Cottier B, López Torrecilla J, Bilbao P, Taillet M, Borras JM. Preliminary analysis of the resources in brachytherapy in Europe and its variability of use. Clin Transl Oncol 2006; 8:491-9. [PMID: 16870539 DOI: 10.1007/s12094-006-0049-1] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
PURPOSE The main objective of the program <<Patterns of Care for Brachytherapy in Europe (PCBE)>> is to establish a group with detailed information on brachytherapy throughout Europe. METHODS The data was compiled by the general coordinator, the ESTRO, and the <<National Cancer Services Analysis>> through a website. RESULTS A total of 32 countries reported data from at least 50% of their centres (criteria of inclusion). Countries were grouped in three categories based on the time of incorporation to the European Union. The majority of treatments belonged to gynaecological tumours. A large spread was found regarding workload of specialists depending on centre and group. CONCLUSION Collection of information by a website is a feasible methodology. An increase in brachytherapy treatment was observed in all 3 groups by a rate of more than 20% (year 2002 versus year 1997). These results advocate for the continuation of the PCBE study to demonstrate the development in the field, such as an increase or decrease of patient numbers per tumour category.
Collapse
Affiliation(s)
- F Guedea
- Institut Català d'Oncologia, IDIBELL, L'Hospitalet del Llobregat, Barcelona, Spain.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
41
|
Guix B, Lacorte TM, Guedea F. Quality of life in intermediate or high risk prostate cancer patients treated by 3-D external beam radiotherapy and brachytherapy with or without androgen deprivation. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.14587] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
14587 Background: To elucidate long-term changes in health-related quality-of-life (HRQOL) outcomes by prospectively re-evaluating a cohort of intermediate- or high-risk prostate cancer patients treated by a combination of 3-D External Beam Radiotherapy (EBRT) and Brachytherapy (BT) with or without androgen deprivation (AD). Methods: A cross-sectional survey was administered to 200 consecutive patients with intermediate (Gleason 7 or PSA 10–20 or T2A-B) or high (Gleason >7 and/or PSA >20 and/or >T2B) - Risk Prostate cancer who were treated by EBRT to the prostate followed by BT to the prostate given either by permanent 125-I seeds (LDR) or high dose rate (HDR) implants before treatment and at 6 months interval during 4 years follow-up. The EORTC CLQ-C30 with the PR-25 module was employed. HRQOL was compared among therapy groups. Comparisons between therapy groups was performed using regression models to control covariates. HRQOL of treatment parameters were evaluated. Distribution of responses for bowel-, urinary- and sexual-related functions were analyzed. Results: 200 patients completed the questionnaires. Significant changes in HRQOL were found depending of the time after treatment. After a temporal decline in HRQOL, an improvement owas found during the first 18 months after end of treatment. Significant improvement in the urinary irritative-obstructive performance (p < 0.006) was found after 6 months post-treatment. Bowel domains worsened after therapies (p < 0,05) but improved after 18 months follow-up (p < 0.02). Overall sexual HRQOL deteriorated depending greatly on treatment (p < 0.008). Patients who were given AD presented a significant lower Sexual Function values, that were difficult to recover after AD cessation (p < 0.007). No differences in HRQOL were found between LDR or HDR BT implants. Satisfaction with either treatment was high. Conclusions: After a decline in HRQOL after treatment, it recovered fully during follow-up. In patients treated by AD, sexual function was the most adversely affected quality-of-life domain. Sexual impairment induced by AD was difficult to recover. These results may be of assistance to men and to clinicians when making treatment decisions, mainly relating AD. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- B. Guix
- IMOR Foundation, Medical Institute for Radiotherapy & Brachytherapy, Barcelona, Spain; Imor Foundation, Barcelona, Spain
| | - T. M. Lacorte
- IMOR Foundation, Medical Institute for Radiotherapy & Brachytherapy, Barcelona, Spain; Imor Foundation, Barcelona, Spain
| | - F. Guedea
- IMOR Foundation, Medical Institute for Radiotherapy & Brachytherapy, Barcelona, Spain; Imor Foundation, Barcelona, Spain
| |
Collapse
|
42
|
Abstract
INTRODUCTION In 2003 ESTRO began a project whose primary objective, was to make a map in the European area of infrastructures in technology and personnel for brachytherapy. MATERIAL AND METHOD A survey and a web site were elaborated. The survey was sent to the 76 Spanish Radiation Oncology departments in May 2003. RESULTS By the end of 2003, 66 (86.8%) services had responded, 40 (71.4%) of which had brachytherapy. The services with brachytherapy treated 73.5% of the total patients, an average of 1,199 patients. The mean number of patients treated with brachytherapy by department was 135.5 and the number of applications was 265 annually. The average number of specialists was 7, 4 of them trained in brachytherapy. The average weekly work load of the radiation oncologists, physicists, and technicians was 22.6 h, 13.8 h and 21.0 h, respectively. The mean time dedicated to each patient by radiation oncologists, physicists and technicians was 9.2 h; 6.19 h; 7.2 h, respectively. The total number of afterloaders was 43 (22 HDR, 18 LDR, 3 PDR). The tumours most frequently treated with brachytherapy were gynaecological (56.24%), breast (14.2%) and prostate (11.7%). High dose rate was used in 47.46% of the patients and low dose rate in 47.24%. Between 1997 and 2002 there was an increase of 50.53% in patients treated with brachytherapy. CONCLUSIONS The survey shows the brachytherapy resources and activity in Spain up to 2003. Increased use of brachytherapy in prostate tumours, prevalence of gynaecology brachytherapy and similar number of treatments with HDR and LDR are demonstrated in the Patterns of Care of Brachytherapy in Europe (PCBE) study in Spain.
Collapse
Affiliation(s)
- J López Torrecilla
- Servicio de Oncología Radioterápica-ERESA, Hospital General Universitario, Valencia, Spain.
| | | | | | | | | | | |
Collapse
|
43
|
Langley S, Laing R, Henderson A, Aaltomaa S, Kataja V, Palmgren JE, Bladou F, Salem N, Serment G, Nava L, Losa A, Guazzoni G, Guedea F, Aguilo F, Suarez JF. European Collaborative Group on Prostate Brachytherapy: Preliminary Report in 1175 Patients. Eur Urol 2004; 46:565-70; discussion 570. [PMID: 15474264 DOI: 10.1016/j.eururo.2004.06.008] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 06/15/2004] [Indexed: 11/20/2022]
Abstract
OBJECTIVE To establish a multi-centre database of a large number of patients treated with brachytherapy across Europe. METHODS A total of 1175 patient files were registered in the database and the completeness of the data on these patients resulted in the majority being included in the analysis. RESULTS The database of patients treated with brachytherapy across Europe indicates that optimal patient selection for this procedure has been made, both in terms of outcome and side-effects, which will be subject of future analyses. This should enable refinement of the treatment choice and administration as well as provide useful guidance to other centres that want to establish this procedure for their patients. It will also set the ground for prospective studies. CONCLUSIONS The established database indicates that brachytherapy as a treatment option for prostate cancer is well established in many centres.
Collapse
Affiliation(s)
- S Langley
- Department of Urology, St Luke's Cancer Centre, Royal Surrey County Hospital, Stirling Road, Guildford, Surrey GU2 5XX, UK.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
44
|
Abstract
Prostate cancer is an important health problem, mainly in elderly men. It is the second cause of death among men in USA ant the third at the "Registro del Cáncer de Tarragona", behind both the lung and colorectal cancer. About the 58% of the newly diagnosed cancers are localized, therefore, they have to be treated with curative intention. Radical prostatectomy is considered the gold standard treatment for organ confined prostate cancer in our country. On basis to the experience of American groups and the improvement of both, image techniques and dosimetric calculation, brachytherapy has been brought in as a new option in the treatment of localized prostate cancer. We started our program of brachytherapy for prostate cancer on May 2000. We have performed 51 procedures by now. Our protocol and the technique to perform a prostatic brachytherapy are described following.
Collapse
Affiliation(s)
- F Aguiló Lucia
- Servicio de Urología, Ciutat Sanitaria i Universitaria de Bellvitge, Barcelona
| | | | | | | | | | | | | |
Collapse
|
45
|
Caminal Mitjana JM, Quintana Casany M, Pera Fábregas J, Cinos Cope C, Guedea F. [Results of Iodine-125 radiotherapy in the treatment of uveal melanoma]. Arch Soc Esp Oftalmol 2002; 77:29-38. [PMID: 11813118] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/23/2023]
Abstract
PURPOSE To evaluate our experience in the treatment of uveal melanoma by means of Iodine-125 brachytherapy. A reprospective case series study. MATERIAL AND METHOD Patients diagnosed of uveal melanoma and treated with Iodine-125 brachytherapy in the Ciudad Sanitaria y Universitaria de Bellvitge (CDUV), from September 1996 to December 2000 and follow up of more than one year. RESULTS During the period of study, 145 patients were diagnosed of uveal melanoma, of which, 77 were treated with Iodine-125 COMS type plaques; among these, 58 were elegible for this study. After a mean of 2.4 year follow up period (878 days) a mean reduction in height of 53.84% and a mean reduction in volume of 75.88% was observed. As for visual acuity, 32.7% of patients presented a vision of 0.1 or better in last follow up check; 13.5% presented low vision at the moment of diagnosis and continued the same up to last follow up check. The rest of patients experienced loss which conditioned vision to less than 0.1. As for complications, we have observed transient diplopia (8.6%), cataract (3.4%), vitreous bleeding (10.3%), neovascular glaucoma (6.8%), radiation retinopathy (17.24%), radiation neuropathy (6.8%), posterior scleritis (2%), pigmental scattering (2%), tumor progression (2%), endophtalmitis (2). Secondary enucleations were carried out in 6.8% of patients. Metastatic disease was observed in 15.5% of the patients. CONCLUSIONS Brachytherapy with Iodine-125 may induce significant regression in most of patients affected of uveal melanoma, with good preservation of visual acuity and a low rate of complications.
Collapse
Affiliation(s)
- J M Caminal Mitjana
- Ciutat Sanitaria i Universitaria de Bellvitge, L'Hospitalet, Barcelona, España
| | | | | | | | | |
Collapse
|
46
|
Moreno F, Guedea F, Lopez Y, Ferrer F, Gutierrez C, Petriz L, Pera J. External beam irradiation plus (192)Ir implant after breast-preserving surgery in women with early breast cancer. Int J Radiat Oncol Biol Phys 2000; 48:757-65. [PMID: 11020573 DOI: 10.1016/s0360-3016(00)00676-3] [Citation(s) in RCA: 19] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
PURPOSE To provide more information for the clinician and to analyze the impact of the boost with brachytherapy on the local disease-free survival (LDFS), disease-free survival (DFS), specific overall survival (OS), and cosmesis, a retrospective study of external radiation therapy and (192)Ir implantation in early breast cancer at Institut Català d'Oncologia has been undertaken. PATIENTS AND METHODS From 1986 to 1996, 530 patients were selected for this study with a median follow-up period of 39.5 months (range, 10-115 months). External radiation therapy (combined with brachytherapy) was administered postoperatively to the breast in all patients. Mean given dose was 48.7 Gy (range, 42-52 Gy) with external radiation therapy to the breast, and 16.8 Gy (range, 10-27 Gy) was the mean dose with brachytherapy. Variables have been tested for cosmesis. Univariate and multivariate analysis have also been carried out. RESULTS Mean age of the patients was 54 years (range, 28-81 years). Stages were distributed as follows: 350 patients (66%) in Stage I, 173 in Stage II (32.8%), and 7 in Stage III (1.1%). Pathologic distribution was 445 patients with infiltrating ductal carcinoma (84%), 20 patients with infiltrating lobular carcinoma (4%), and 65 patients (12%) of a miscellaneous group. OS for the entire group was 89.4% and 85.9% at 5 and 7 years respectively. Probability of DFS was 81.7% and 70.1% at 5 and 7 years. The LDFS was 94.9% and 91.7% at 5 and 7 years. The MFS probability was 85.5% and 76.9% at 5 and 7 years, respectively. Univariate analysis demonstrated that age (older than 52 years), premenopausal status, moderate and high histologic grades (Grades II-III), and presence of intraductal comedocarcinoma were prognostic factors for local relapse. Multivariate analysis for local disease-free survival demonstrated that only perineural or muscular infiltration remain as prognostic factors. Tumor dose bed of 70 Gy or higher had a negative impact in breast subcutaneous fibrosis, whereas dose rate lower than 65 cGy/h was better for skin color at 2 years. CONCLUSION We conclude that patients with early-stage breast cancer undergoing external radiotherapy and LDR brachytherapy can be effectively managed. Overall survival, long-term local control, and cosmetic control are excellent.
Collapse
MESH Headings
- Adult
- Aged
- Aged, 80 and over
- Analysis of Variance
- Brachytherapy/methods
- Breast Neoplasms/pathology
- Breast Neoplasms/radiotherapy
- Breast Neoplasms/surgery
- Carcinoma, Ductal, Breast/pathology
- Carcinoma, Ductal, Breast/radiotherapy
- Carcinoma, Ductal, Breast/surgery
- Carcinoma, Lobular/pathology
- Carcinoma, Lobular/radiotherapy
- Carcinoma, Lobular/surgery
- Combined Modality Therapy
- Disease-Free Survival
- Female
- Follow-Up Studies
- Humans
- Iridium Radioisotopes/therapeutic use
- Mastectomy, Segmental
- Middle Aged
- Neoplasm Staging
- Radiotherapy Dosage
- Retrospective Studies
Collapse
Affiliation(s)
- F Moreno
- Department of Radiation Oncology, Institut Català d'Oncologia, Barcelona, Spain
| | | | | | | | | | | | | |
Collapse
|
47
|
Ferrà C, Servitje O, Pétriz L, Estrach T, Martí R, Limón A, Gutierrez C, Blanco A, Guedea F, Peyrí J, Grañena A. Autologous haematopoietic progenitor transplantation in advanced mycosis fungoides. Br J Dermatol 1999; 140:1188-9. [PMID: 10354105] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/12/2023]
|
48
|
Ferrer F, Sabater S, Farrús B, Guedea F, Rovirosa A, Anglada L, Delannes M, Marín S, DuBois JB, Daly-Schveitzer N. Impact of radiotherapy on local control and survival in uterine sarcomas: a retrospective study from the Grup Oncologic Català-Occità. Int J Radiat Oncol Biol Phys 1999; 44:47-52. [PMID: 10219793 DOI: 10.1016/s0360-3016(98)00515-x] [Citation(s) in RCA: 56] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
PURPOSE In order to provide more information for the clinician and to analyze the impact of radiation therapy on the loco-regional disease-free interval (LRFI), disease-free interval (DFI) and specific overall survival (OS), a multicentric retrospective study of uterine sarcomas has been undertaken using cases reported to the Grup Oncològic Català-Occità (GOCO). PATIENTS AND METHODS One hundred three patients were selected for this study with a median follow-up period of 49 months. Patients were restaged using the FIGO classification for endometrial adenocarcinoma. Radiotherapy was administered postoperatively to the entire pelvis in 52% of cases (54/103) and was combined with brachytherapy in 24 patients. Mean given dose was 48 Gy, with a 95% confidence interval of 45 to 50 Gy. Variables have been tested for homogeneity between hospitals. Univariate and multivariate analyses have also been carried out. RESULTS Mean age of the selected patients was 59 years (range 35-84). Stages were distributed as follows: 66 patients (64%) in Stage I; 16 in Stage II (15.5%); 12 in Stage III (11.5%); 9 patients in Stage IVa (9%). Pathological distribution was 41.5% leiomyosarcoma, 39% mixed Mullerian tumours, 16.5% stromal sarcomas, and 2.9% of a miscellaneous group. Overall survival for the entire group was 63.7% and 56% at 2 and 5 years, respectively. Probability of LRFI reached 59.8% at 2 years and 57.4 at 5 years. The DFI at 2 and 5 years were 52.9 % and 48.7%, respectively. The LRFI probability was 41% and 36% at 2 and 5 years, respectively, without radiotherapy and reached 76% at 2 and 5 years among those patients treated with radiotherapy. There was also an increase in DFI probability because of the effect of radiotherapy, from 35% to 68.5% and from 33% to 53% at 2 and 5 years, respectively. The overall survival probability for patients treated with radiotherapy was 76% and 73% at 2 and 5 years, respectively and 51% at 2 years and 37% at 5 years without radiotherapy. Multivariate analysis demonstrated that radiotherapy improved LRFI, DFI, and overall survival. CONCLUSION We conclude that postoperative radiotherapy in our series of patients diagnosed with uterine sarcoma has an impact on loco-regional and disease-free progression intervals and survival.
Collapse
Affiliation(s)
- F Ferrer
- Department of Radiotherapy, Hospital Clínic i Universitari, Barcelona, Spain.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
49
|
Pera J, López Y, Moreno F, Gutierrez C, Prieto L, Gil M, Lloveras B, Guedea F. 5Long-term outcome with interstitial brachytherapyin the management of patients with early-stage breast cancer treated with breast-conserving therapy. Radiother Oncol 1998. [DOI: 10.1016/s0167-8140(98)80010-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
50
|
León X, Quer M, De Juan M, Vega M, Guedea F, Venegas MP, Burgués J. [Results of salvage treatment of carcinoma of the larynx recurring after radiotherapy]. Acta Otorrinolaringol Esp 1997; 48:537-43. [PMID: 9489155] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
An analysis is made of salvage treatments and their results after unsuccessful radiotherapy in 113 carcinomas of the larynx. A group of 27 patients (24%) was excluded from salvage treatment. In the remaining 86 patients (76%), radical surgical salvage treatment was tried: total laryngectomy (74 cases) or partial surgery (12 cases). Four of the 12 patients treated with partial surgery suffered a second local relapse, which was rescued by new surgery. Treatment was successful in 72% of the laryngectomized patients and in all those treated with partial surgery. Survival correlated with local (T) and regional (N) extension of the initial tumor, its location, and simultaneous regional relapse. In contrast, survival did not correlate with the time interval between end of radiotherapy and relapse, or with local tumoral extension in the resection piece in surgically treated cases (rpT).
Collapse
Affiliation(s)
- X León
- Servicio de ORL, Hospital de la Sta, Creu i Sant Pau, Universitat Autònoma de Barcelona
| | | | | | | | | | | | | |
Collapse
|